MedPage Today January 24, 2022
— Feds lead investment in antimicrobial resistance, but more private help is needed, BARDA says
However, “[i]nnovation has been extremely slow,” the editorial continued. “Vaccines are available for only one of the six leading pathogens … The clinical pipeline for antibiotics is too small to tackle the increasing emergence and spread of AMR.”
“National leaders now have an obligation to move AMR to a higher position in their political agendas,” the editorialists argued. “Research efforts should be accelerated to address knowledge and innovation gaps and to inform policy and practices.”
The day before the editorial’s publication, MedPage Today spoke with Chris Houchens, PhD, director of the division of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures for the Biomedical Advanced...
Today's Sponsors
Today's Sponsor